CONQUER CANCER®
THE ASCO FOUNDATION

2025 CONQUER CANCER – BREAST CANCER RESEARCH FOUNDATION® ADVANCED CLINICAL RESEARCH AWARD (ACRA) FOR DIVERSITY AND INCLUSION IN BREAST CANCER RESEARCH

REQUEST FOR PROPOSALS

Last Updated: December 17, 2024

Letter of Intent Deadline: January 31, 2025

Conquer Cancer®, the ASCO Foundation
2318 Mill Road, Suite 800
Alexandria, VA 22314
grants@conquer.org

Please visit asco.org/ACRA for the most up-to-date version of the Request for Proposals.

About Conquer Cancer®, the ASCO Foundation

Conquer Cancer funds research for every cancer, every patient, everywhere. Since 1984, its Grants & Awards program has awarded more than $190 million through more than 9,200 grants and awards to improve cancer care and accelerate breakthroughs in clinical and translational oncology research. Conquer Cancer donors support vital programs needed to deliver the highest quality, equitable patient care and share a vision of a world where cancer is prevented or cured, and every survivor is healthy. For more information visit CONQUER.ORG.

Table of Contents

Purpose

The Conquer Cancer – Breast Cancer Research Foundation Advanced Clinical Research Award (ACRA) for Diversity and Inclusion in Breast Cancer Research is designed with the primary goal of increasing diversity in the oncology workforce and breast cancer research. Awards will be given to mid-career investigators who identify as members of populations underrepresented in medicine[1] (UIM), and who wish to conduct original breast cancer research not currently funded.

Increasing diversity and inclusion in the oncology and academic research workforce is vital to ensuring that all researchers who wish to contribute to cancer research are able to do so. A diverse oncology workforce representing different backgrounds with respect to race or ethnicity, socioeconomic status, geography, culture, gender and other factors is critical, to be able to collectively understand and relate to issues affecting their patient's health and access to care. Diverse healthcare teams yield to an increased patient trust, satisfaction and more equitable patient outcomes. The Breast Cancer Research Foundation® (BCRF) and Conquer Cancer are committed to helping diverse researchers advance in their careers through direct funding.

The lack of representation in cancer research also contributes to a pernicious reality for Black patients with breast cancer in the United States. While overall breast cancer mortality rates declined by 40 percent over the last 30 years, these improvements are not distributed equitably, and African American patients are 40 percent more likely to die from their disease than white patients. The reasons for this disparity are complex and multifactorial, stemming from policies which have historically exacerbated systemic gaps in cancer care and outcomes.

BCRF is a nonprofit organization committed to achieving prevention and a cure for breast cancer. BCRF is committed to diversity, equity and inclusion, and has signed the Tigerlily Diversity and Inclusion Pledge for Women of Color. More specifically, BCRF is actively working to: increase diversity within its organization at all levels, from staff and leadership to scientists funded; improve diversity in clinical trials; continue to maintain—and expand—a robust research portfolio that attacks racial disparities in breast cancer outcomes and care from all angles.

Commitment to Health Equity, Diversity, and Inclusion and Global Impact

Conquer Cancer supports ASCO's strategic plan, which embeds equity, diversity and inclusion (EDI) and making a global impact as two cross-cutting themes throughout the organizations. The commitment to these areas reflects an intention to lead the fight for cancer equity by ensuring every person with cancer, regardless of who they are, or where they live, has access to high quality, equitable prevention, early

[1] ASCO and Conquer Cancer define underrepresented in medicine (UIM) as those who self-identify from a UIM population which includes individuals from racial and ethnic groups including Blacks or African Americans, Hispanics or Latinos, American Indians or Alaska Natives, Native Hawaiians and other Pacific Islanders; individuals with disabilities; and individuals from disadvantaged backgrounds. In addition, this definition of UIM recognizes that underrepresentation can vary from setting to setting; those with impacted life experiences, such as discrimination, socioeconomic status, historically underserved, or otherwise individuals that can be demonstrated to be underrepresented by the applicant's institution.

detection, treatment and support services. Conquer Cancer and ASCO are committed to facilitating the eradication of disparities in cancer outcomes, promoting research that benefits all populations, and working collaboratively across the oncology community in pursuit of this mission. This includes an effort to support research by and for those who are underrepresented in medicine and from low and middle-income countries. Addressing inequities in cancer care includes improving representation of all populations who stand to benefit from the research. Every person with cancer should have an equal opportunity to participate in, be recognized for, and benefit from research across the spectrum, including clinical trials, health services research, and other types of research studies and methodologies.

Funding Available

The total award amount is $**450,000 over three years**, payable in annual increments of $150,000. Conquer Cancer has funding for two BCRF ACRAs for Diversity and Inclusion in Breast Cancer Research which will be awarded to the most meritorious applications evaluated for this competition.

Eligibility Criteria

Applicants must meet the following criteria for the ACRA for Diversity and Inclusion in Breast Cancer Research:

- Self-identify as a member of populations underrepresented in medicine (UIM)
- Be a physician (MD, DO, or international equivalent).
- Have completed productive post-doctoral/post fellowship research and demonstrated the ability to undertake independent investigator-initiated clinical research in breast cancer.
- At mid-career level, normally between five to ten years from the first, full-time, primary faculty appointment in a clinical department at an academic medical institution by the application deadline.
- Be an ASCO member or have submitted a membership application with the grant application. To apply for new membership, or to renew an existing membership, go to asco.org/membership.
- Be able to commit 75 percent of full-time effort in research (applies to total research, not just the proposed project) during the award period.
- Applicants who have previously received other grants from Conquer Cancer must be up-to-date and in compliance with all requirements (e.g. progress reports, final reports, budget summaries, IRB approvals, etc.) of any past grants.

Eligible applicants are allowed to hold only one active grant from Conquer Cancer at a time.

There are no citizenship or geographic requirements. However, by submitting an application, an applicant applying from an institution located in a country in which they are not a citizen or a permanent resident assures that the visa status will provide sufficient time to complete the project and grant term at the institution from which they applied.

The Conquer Cancer Diversity and Inclusion in Breast Cancer Research Subcommittee reserves the right to evaluate and determine an applicant's eligibility based on the information and justifications included in the application materials. **Applicants who are uncertain about their eligibility are encouraged to**

refer to the Eligibility section of the FAQ or contact grants@conquer.org for clarification and provide their latest CV for evaluation.

Research Project Criteria

The ACRA for Diversity and Inclusion in Breast Cancer Research is intended to support original proposals, including a clinical research study and/or translational research involving human subjects from eligible investigators who wish to conduct original breast cancer research not currently funded. ASCO's definition of clinical research is "hypothesis-driven research that employs measurements in whole patients or normal human subjects, in conjunction with laboratory measurements as appropriate; on the subjects of clinical biology, natural history, prevention, screening, diagnosis, therapy, or the epidemiology of neoplastic disease" (*Journal of Clinical Oncology,* Vol. 14, No. 2, 1996, pp. 666-670). Project proposals should have measurable outcomes during the three-year grant period.

ACRA proposals must ensure that the research reflects the needs of cancer patients and must be developed with the participation of a patient advocate. Please refer to page 15 of this RFP for additional information about engaging a patient advocate in the ACRA project.

Peer Review of Applications

The applications are reviewed by the Conquer Cancer ACRA for Diversity and Inclusion in Breast Cancer Research Subcommittee using a multi-stage review process. Each application is assigned to at least two scientific reviewers who are leaders in their areas of expertise for independent and confidential review. **Applications that reach the final stage are also reviewed by a biostatistician and a patient advocate.**

The applications are evaluated and scored by the Committee based on the following criteria using the 1-9 NIH scoring scale.

Review and Selection Criteria:

- Strength of the hypothesis-driven proposal with a clinical research focus on breast cancer
- Focus on patient-oriented research
- Significance and originality of the proposed study and hypothesis
- Appropriateness, feasibility, and adequacy of the proposed experimental design and methodology
- Availability of environmental and institutional resources to support the proposed project
- Prior research experience and accomplishments of the applicant
- Potential favorable impact on career development of the applicant

Key Dates

Letter of Intent Due:	**January 31, 2025 by 11:59 PM ET**
Letter of Intent Notifications:	**LOIs will be approved on a rolling basis but no later than January 31, 2025**
Full Application Due:	**March 13, 2025 by 11:59 PM ET**
Award Notification Date:	**April 2025**
Award Term:	**July 1, 2025 – June 30, 2028**

Application Changes

The applicant must notify Conquer Cancer immediately by sending an email to grants@conquer.org if any of the following condition applies from application submission through award notification:

1. Withdrawal of Application. Send an email to grants@conquer.org to inform the Conquer Cancer Grants and Awards team of the reason(s) for withdrawing the application. The email should include the applicant's name, the title of the proposal, and the reason for withdrawing the application.

2. Change of Institution or Position. The applicant has a career plan change, leaves their current position in the institution, or is unable to meet the eligibility requirements of this RFP. If the applicant is selected to receive an ACRA, Conquer Cancer has the right in its sole discretion to withdraw the award.

3. Change in Proposal (Scope, Timeline, Budget, etc.). The applicant has significant changes in the submitted proposal affecting aims, research strategy, timeline, and/or budget. If Conquer Cancer is notified of the change in proposal after the applicant is notified of an award, Conquer Cancer has the right in its sole discretion to withdraw the award.

Changes in institution or project scope after an award notification will require additional documents and review and approval from Conquer Cancer. Conquer Cancer has the right in its sole discretion to withdraw the award.

Award Notification

Applicants can expect to be notified in April 2025 via email from awards@mail.asco.org. To ensure receipt of notifications from the application portal, it is highly recommended to include awards@mail.asco.org to the applicant's safe sender list. All communication regarding applications, including award notifications, will be sent to the preferred email address on the applicant's membership profile. For questions, please contact grants@conquer.org.

Application Procedures

The ACRA contains two phases: a Letter of Intent (LOI) phase and a Full Application phase. Completion of the Full Application is by invitation-only based on the submitted LOI.

All applications must be submitted in accordance with the requirements and instructions of this Request for Proposals (RFP). All application materials must be in English and must be submitted online through the ASCO and Conquer Cancer application portal at awards.asco.org. No paper applications sent by mail, e-mail, or fax will be accepted.

Applicants are encouraged to start their application early due to the complexity of the online application process. The LOI must be submitted by **11:59 PM ET on January 31, 2025**. No late applications will be accepted. Please note that technical assistance is only available until 5:00 PM ET on the due date.

Helpful Tips for Using the Application Portal are included in Appendix B.

PHASE 1: LETTER OF INTENT

Sections of the LOI are listed below. More details about each section, including requirements and instructions, are described in the succeeding pages:

1. Applicant Information (required)
2. Project Information (required)
3. Applicant's Biosketch (required)
4. Review and Submit (required)

1. **Applicant Information (required).** This section includes the following:
   - Applicant Information. This information is pulled directly from the applicant's ASCO membership profile. If changes need to be made to the applicant's information, visit profile.asco.org. **Please make sure that the applicant's profile has the most up-to-date information before beginning an application**. Changes made to the applicant's profile are not saved in real-time but will be reflected on this form before submitting the full application.
     - First Name
     - Middle Name
     - Last Name
     - Degree
     - Race and Ethnicity (this field is not visible in the application portal; *applicant should self-identify race/ethnicity in their ASCO membership profile*)
     - Primary Organization Name
     - Address (including city, state, and zip code)
     - Country
     - Primary email address (all future communications about the application will be sent to this address)
     - ORCID ID
     - ASCO Member ID
   - Additional questions and required information. Answer the following:
     - Do you have a medical degree or international equivalent?
     - Do you have a full-time faculty appointment?
     - Academic Rank. Select from the drop-down list.
     - Certification/Subspecialty Training. Select from the drop-down list.
     - Field of Clinical Training. Select all that apply
     - Field of Research Training. Select all that apply.
   - After completing this form, click **"Mark as Complete"**.

2. **Project Information (required).** This section includes the following proposed project information (all are required):
   - Research Project Title (250 characters maximum): Provide a short descriptive title of the research project.
   - Brief Research Project Description/Abstract (3000 characters maximum): Provide a brief abstract of the research project.
   - Lay Abstract (2500 characters maximum). Provide a layperson summary of the project. Describe the work in a way that it will be understood by people who do not have scientific or medical backgrounds. Be clear and avoid technical and scientific terms when possible. It should not include confidential information. If selected to receive an award, Conquer Cancer may use the content of this layperson summary on its website and/or other public facing materials.
   - Specific Aims (1000 characters maximum per aim): Select the number of aims from the drop-down list. Briefly describe the goals of each aim separately and concisely in the boxes provided. Include the following for each aim: the aim objective (e.g., to test a stated hypothesis, create a novel design, solve a specific problem, challenge an existing paradigm or clinical practice, address a critical barrier to progress in the field, or develop new technology), the research

approach, and the expected outcomes. At least one specific aim is required. Details (e.g., background, rationale for each aim and alternative strategy) for respective aims can be included in the research strategy section.

- Subject Area: Select one Subject Area from the drop-down list that best describes the research project, its objectives and proposed project outcomes. If "Other" is selected, provide information in the text field.
- Focus Area(s): Select all that apply. If "Other" is selected, provide information in the text field.
- Equity, Diversity, and Inclusion: Select "Yes" or "No" in response to the question "Does your research project address health disparities and inequities?"
- Research Classification: Select a category that relates to the research project. The list has six broad categories of scientific interest in cancer research.
- Type of Research Study: Select an option from the drop-down list.
    - If "Clinical" is selected, indicate the clinical trial phase and clinical trial number or identifier.
    - Assurances: Human Subjects. Indicate whether human subjects will be involved in the research. If yes, select the appropriate status.
        - If the status is Approved, enter the IRB Approval Date, IRB Expiration Date, and Assurance Number.
        - If the status is Exempt, enter the Exemption Number.
        - If the status is Pending, please indicate the anticipated date of approval and enter any additional comments in the comment box.
- Use of Drug(s): Indicate if the research involves the use of drug(s). If yes, enter the name of the drug(s) and the drug manufacturer(s). It is highly encouraged to include a letter from the manufacturer(s) or supplier(s) that they will provide the drug in the Supporting Documentation section of the application.
- Resubmission: Select "Yes" or "No" from the drop-down list to indicate if the application is a resubmission of a previous application.
- After completing this form, click **"Mark as Complete"**.

3. **Applicant's Biosketch (required).** Applicants should use the NIH biosketch template provided with an expiration date of 01/31/2026. The biosketch must not exceed more than five (5) pages. To complete the biosketch, please refer to these instructions. **If the document uploaded exceeds the page limit, Conquer Cancer will return the application.**

   Upload as a PDF file. Click "**Attach File**" and select the file to be uploaded in the application.

   Use this file naming convention: *[year program abbreviation]_Biosketch_[Last name] (e.g., 2025ACRA_Biosketch_your last name)*

   After completing this form, click **"Mark as Complete"**.

4. **Review and Submit (required).**
   The applicant will not be able to navigate to this page until all required sections have been **"Marked as Complete"**.

   On the left navigation, click **"Review"** to review or **"Submit"** to submit the application.

To download a copy of the application, click "**My Applications**". Click the ellipsis **(…)** on the specific application and click "**Download**".

On the next screen, select the desired options and click "**Download**".

A new tab will open. Once the download is ready, click "**Download**". The application will be downloaded as a zip file.

Letter of Intent Review Criteria and Notification

The LOI will be reviewed internally by Conquer Cancer based on the following criteria:

(1) Completeness of information and adherence to instructions for submission;
(2) Eligibility, and;
(3) Appropriateness of scientific focus of the proposal.

After review, applicants will be notified on a rolling basis no later than **January 31, 2025** about the status of their LOI. **Only applicants who have received an approval for their LOI will be eligible to submit a full application.**

PHASE 2: FULL APPLICATION

Sections of the full application are listed below. More details about each section, including requirements and instructions, are described in the succeeding pages:

1. Applicant Information (required)
2. Project Information (required)
3. Research Strategy (required, 6 pages maximum)
4. Biostatistical Section (required, 1 page maximum)
5. Cited References (required)
6. Patient Impact Section (required)
7. Budget (required)
8. Project Timeline Form (required)
9. Resubmission Documentation (required for resubmissions, 1 page maximum)
10. Personal Statement Form (required)
11. Applicant's Biosketch (required, 5 pages maximum)
12. Institutional Letter of Support from Department Chair or Dean (required)
13. Clinical Protocol (required) – strongly encouraged
14. Letter from Drug Company (optional)
15. Publication Form (optional) – maximum of two publications
16. Additional Supporting Documentation (optional)
17. Institutional Approval (required)
18. Review and Submit (required)

Note: Information previously entered in the Letter of Intent may appear in some sections. Please edit the existing information as necessary.

1. **Applicant Information (required).** This section includes the following:
   - Applicant Information. This information is pulled directly from the applicant's ASCO membership profile. If changes need to be made to the applicant's information, visit profile.asco.org. Please make sure that the applicant's profile has the most up-to-date information. Changes made to the applicant's profile are not saved in real-time but will be reflected on this form before submitting the full application.
     - First Name
     - Middle Name
     - Last Name
     - Degree
     - Race and Ethnicity (this field is not visible in the application portal; *applicant should self-identify race/ethnicity in their ASCO membership profile*)
     - Primary Organization Name
     - Address (including city, state, and zip code)
     - Country
     - Primary email address (all future communications about the application will be sent to this address)
     - ORCID ID
     - ASCO Member ID
   - Additional questions and required information. Answer the following:
     - Do you have a medical degree or international equivalent?
     - Do you have a full-time faculty appointment?
     - Academic Rank. Select from the drop-down list.
     - Certification/Subspecialty Training. Select from the drop-down list.
     - Field of Clinical Training. Select all that apply
     - Field of Research Training. Select all that apply.
   - After completing this form, click **"Mark as Complete"**.

2. **Project Information (required).** This section includes the following proposed project information (all are required):
   - Research Project Title (250 characters maximum): Provide a short descriptive title of the research project.
   - Brief Research Project Description/Abstract (3000 characters maximum): Provide a brief abstract of the research project.
   - Lay Abstract (2500 characters maximum). Provide a layperson summary of the project. Describe the work in a way that it will be understood by people who do not have scientific or medical backgrounds. Avoid technical and scientific terms. Do not include confidential information. If selected to receive an award, Conquer Cancer may use the layperson summary on its website and/or other public facing materials.
   - Specific Aims (1000 characters maximum per aim): Select the number of aims from the drop-down list. Briefly describe the goals of each aim separately and concisely in the boxes provided. Include the following for each aim: the aim objective (e.g., to test a stated hypothesis, create a novel design, solve a specific problem, challenge an existing paradigm or clinical practice, address a critical barrier to progress in the field, or develop new technology), the research

approach, and the expected outcomes. At least one specific aim is required. Details (e.g., background, rationale for each aim and alternative strategy) for respective aims can be included in the research strategy section.

- Subject Area: Select one Subject Area from the drop-down list that best describes the research project, its objectives and proposed project outcomes. If "Other" is selected, provide information in the text field.
- Focus Area(s): Select all that apply. If "Other" is selected, provide information in the text field.
- Equity, Diversity, and Inclusion: Select "Yes" or "No" in response to the question "Does your research project address health disparities and inequities?"
- Research Classification: Select a category that relates to the research project. The list has six broad categories of scientific interest in cancer research.
- Type of Research Study: Select an option from the drop-down.
    - If "Clinical" is selected, indicate the clinical trial phase and clinical trial number or identifier.
- Assurances: IRB and IACUC approvals are not required at the time of submission but highly encouraged to provide documentation.
    - Human Subjects. Indicate whether human subjects will be involved in the research. If yes, select the appropriate status.
        - If the status is Approved, enter the IRB Approval Date, IRB Expiration Date, and Assurance Number.
        - If the status is Exempt, enter the Exemption Number.
        - If the status is pending, please indicate the anticipated date of approval in the comment box.
- Use of Drug(s): Indicate if the research involves the use of drug(s). If yes, enter the name of the drug(s) and the drug manufacturer(s). It is highly encouraged to include a letter from the manufacturer(s) or supplier(s) that they will provide the drug in the Supporting Documentation section of the application.
- Resubmission: Select "Yes" or "No" from the drop-down list to indicate if the application is a resubmission of a previous application.
- After completing this form, click **"Mark as Complete"**.

3. **Research Strategy (required).** The research strategy is limited to six (6) typewritten, single-spaced pages, with one-inch margins and using an 11-point Arial font type. ALL pertinent tables, pictures, and graphs MUST be included within the 6-page limit. **If the document uploaded exceeds the page limit, Conquer Cancer will return the application.**

   The Research Strategy must contain the following information:

   i. Significance and Background:
      A. Explain the importance of the problem or critical barrier to progress in the field that the proposed project addresses.
      B. Explain how the proposed project will improve scientific knowledge, technical capability, patient care, and/or critical practice in one or more broad fields.
      C. Describe how the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field will change if the proposed aims are achieved.

ii. Innovation:
   A. Explain how the application challenges and seeks to shift current research, clinical practice paradigms, or patient care.
   B. Describe any novel theoretical concepts, approaches or methodologies, instrumentation or interventions to be developed or used, and any advantage over existing methodologies, instrumentation, or interventions.
   C. Explain any refinements, improvements, or new applications of established theoretical concepts, approaches or methodologies, instrumentation, or interventions.

iii. Approach:
   A. Describe the overall strategy, methodology, and analyses to be used to accomplish the specific aims of the project. Include how the data will be collected, analyzed, and interpreted as well as any resource sharing plans as appropriate. For clinical trials, briefly describe any inclusion and exclusion criteria, and their rationale.
   B. When patients are involved, the precautions to ensure patient safety and confidentiality, minimize patient burdens, and the relevance or implications for patient care should be explained.
   C. Describe any strategy and/or relevant data to establish feasibility and address the management of any high-risk aspects of the proposed work. Describe any facilities and resources that will be used to complete the study, including relevant industry support.
      - *Note:* Appropriate documentation (e.g. approvals, collaboration letters) must be uploaded in the Supporting Documentation section to assure a reviewer that the applicant's project is feasible in the timeframe of the grant.

iv. Anticipated Results and Alternative Strategies
   A. Describe the anticipated results and outcomes of the proposed aims, and potential next steps.
   B. Describe any benchmarks that will be used to determine success in the aims and anticipated outcomes.
   C. Discuss limitations in the experimental design, potential problems, and alternative strategies that will be employed if anticipated outcomes are not achieved.

Upload as a PDF file. Click "**Attach File**" and select the file to be uploaded in the application.

Use this file naming convention: *2025ACRA_ResearchStrategy_your last name*

After completing this form, click **"Mark as Complete"**.

4. **Biostatistical Plan (required). Applications will be reviewed and scored by a biostatistical reviewer for statistical rigor.** The applicant is required to closely work with the collaborating biostatistician and/or bioinformatician in developing the research strategy.

Upload the following documents.

i. **Biostatistical Plan (required).** A detailed statistical plan is limited to one (1) typewritten, single-spaced page with one-inch margins and 11-point Arial font type. References, if any for

this section, can be indicated here and provided with other cited references for the proposal to be within the one-page limit. **If the document uploaded exceeds the page limit, Conquer Cancer will return the application.**

All studies whether clinical, observational, in-vivo or laboratory-based in vitro research proposals must include the primary objective/hypothesis, clearly defined endpoint of the study, description of experimental design and study groups that will be compared, justification of the proposed study sample size, detailed procedures for data analysis, and any other appropriate statistical details that describe the summary measures that will be used to meet the objectives of the study. An appropriate sample size justification should include all parameters and assumptions required for the computation of the sample size (including key references if novel methods used, and sufficient enough to allow replication): the effect size, power and type I error rates for each aim where applicable. If Bayesian approaches are used, prior assumptions and operating characteristics should be provided. When relevant to the project, the plan should state the median follow-up, prevalence of mutations in a given population, accrual rate, or number of events for a time-to-event outcome. The statistical analysis plan should provide details for analyzing high-throughput data including the pipelines and procedures, if the proposal involves such data. For studies using artificial intelligence and machine learning techniques, detailed statistical design and analysis plan for algorithms, training data and validation data, performance metrics, and data/software sharing must be included in the proposal.

ii. **Letter(s) of Support (required).** The letter from the collaborating biostatistician and/or bioinformatician should clearly state a mentoring plan including roles and responsibilities of the biostatistician, the support provided with the study design, clinical trials, data analysis, interpretation of findings, and the resources available to ensure statistical rigor and feasibility of the proposed project.

Visit the Application Resources on asco.org. It includes a webinar recording on “Working with a Biostatistician.”

Upload as a PDF file. Click “**Attach File**” and select the file to be uploaded in the application.

Use this file naming convention*:*

2025ACRA_BiostatisticalPlan_your last name
2025ACRA_LOS_your last name

After completing this form, click **“Mark as Complete”**.

5. **Cited References (required).** Upload a bibliography of any references cited in the Research Plan. The Cited References has no page limit, must be typewritten with single-space, one-inch margins and using an 11-point Arial font type.

Upload as a PDF file. Click "**Attach File**" and select the file to be uploaded in the application.

Use this file naming convention: *2025ACRA_CitedReferences_your last name*

After completing this form, click **"Mark as Complete"**.

6. **Patient Impact Section (required). Applications will be reviewed and scored by a patient advocate.** The Patient Impact section should describe how the project will impact patients and describe the role of a patient advocate in the project. The patient advocate reviewer will use this section, among other materials, to assess how well the applicant explains how the proposed project could impact patients, and how the project would address the needs of cancer patients.

   The patient advocate should be involved early during the development of the project and the application. This will help to ensure that the proposed research is relevant to patients, minimizes patient burdens, and addresses their needs efficiently. A patient advocate can include but is not limited to a survivor of or person living with cancer, a family member or primary caregiver of a person living with cancer, or other individual with a strong personal connection or experience with cancer. A patient advocate should have a dedicated interest in cancer research and survivorship and be able to represent the perspective of cancer patients/survivors/co-survivors in the development and conduct of the project.

   Clinical studies must be clearly written, well-designed, and must follow all ethical and Institutional Review Board regulations.

   Applicants are encouraged to work with their mentors to leverage institutional resources, such as community advisory groups or advocacy programs, to identify advocates to work with. Applicants are also encouraged to contact local cancer advocacy groups when appropriate. Whenever possible, applicants are strongly recommended to work with an advocate who has experience with the cancer type to be studied in the proposed research.

   Note: If your institution does not have patient advocates to help in developing your study, please visit the Application Resources on asco.org. It includes a webinar recording on "Working with a Patient Advocate", and article on "Patient Engagement in Cancer Research From the Patient's Perspective" and resources for locating patient advocates involved in cancer research.

   The applicant and patient advocate should:

   - Discuss the project and identify the potential translational and clinical significance of the project from the patient perspective. How will successful completion of the project lay foundation for future translational and clinical research studies?
   - Discuss how the project will affect fundamental concepts in cancer research that are relevant and beneficial to patients, their families and care givers
   - Discuss the research and clinical design of the project.

- Work together to develop the Lay Abstract in the project information section.

Upload the following documents:

i. **Patient Impact Questions (required, template provided).** To inform reviewers of the applicant's proposed research's relevance for patients and to demonstrate that their research will be conducted with the contributions from a patient advocate, applicants must answer questions provided in the template as concisely as possible using lay-friendly language. Limit responses to no more than 2500 characters per question.

ii. **Letter of Support from the Collaborating Patient Advocate (required).** The letter should include a description of the scope of the patient advocate involvement to-date and the expected involvement with the proposed research project as a whole in the future.

Upload as PDF files. Click "**Attach File**" and select the file to be uploaded in the application.

Use this file naming convention*:*
2025ACRA_PA_template_your last name
2025ACRA_PA_LOS_your last name

After completing this form, click "Mark as Complete".

7. **Budget (required).** The award funds will be directed to the Sponsoring Institution and should be used towards salary support, supplies, equipment, travel, etc. necessary for the pursuit of the Applicant's research project. Award funds may not be applied to patient care costs that are reimbursable by a third-party payor, to the Applicant's ASCO membership dues, or to tuition or fees for academic courses.

   The budget must be directly entered into the budget form. Budget justification for the entire period must be entered in the "Description of Costs" column. Enter N/A for budget categories not being requested. The direct and indirect costs will calculate automatically at the bottom of the page as entered.

   The budget guidelines are as follows:
   - Total Award: The total award amount is $450,000 payable on July 1 in annual increments of $150,000 over three years. The total cost requested per year should not exceed $150,000. During the award period, at least 80 percent of the yearly budget must be expended by the end of each reporting year as a condition of approval for payment of the next installment of Award Funds.
   - Research support: At least $137,000 per year should support costs directly related to the research project such as personnel salary, supplies, equipment, and other expenses. Budgeted items must be consistent with available institutional facilities and resources. Patient care costs that are reimbursable by a third-party payor, professional membership dues, tuition fees, and other fees for academic courses and certifications are unallowable costs. Salary limits will be equivalent to the NIH applicable limit.

- Travel: Up to $2,500 per year should be allotted specifically for the Applicant's travel to the ASCO Annual Meeting and for any other travel essential to conducting the study. Attendance is **mandatory** at the Conquer Cancer Grants and Awards Ceremony, which will take place during the ASCO Annual Meeting in May 30 2025. Conquer Cancer approves costs incurred to attend the ASCO Annual Meeting as pre-award costs.
- Indirect costs: Up to $10,500 per year (or 7 percent of the yearly total award amount) may be applied to overhead or facilities and administrative costs of the Applicant's institution in administering the research project.

After completing this form, click **"Mark as Complete"**.

8. **Project Timeline Form (required).** Enter each major project milestone/activity, a brief description, the expected completion date, the status and if it is an associated deliverable **using the required template**. A deliverable is something that can be included in a progress report, such as a publication or an approval letter. The applicant is not required to have deliverables during the award term. However, the timeline should be clear what outcomes will be achieved during the award period and its expected timeframe. The expected date of completion for the major milestones described in each aim of the proposal must be provided.

   Ensure all columns and rows in the completed template are visible on each page and set to proper print area. Upload as a PDF file. Click "**Attach File**" and select the file to be uploaded in the application.

   Use this file naming convention: *2025ACRA_Timeline_your last name*

   After completing this form, click **"Mark as Complete"**.

9. **Resubmission Documentation (required for resubmissions only).** Applicants resubmitting a prior application are **required** to upload a one-page introduction to address the feedback and critiques provided during the prior application cycle.

   The introduction is limited to one (1) typewritten, single-spaced page with one-inch margins and 11-point Arial font type. This introduction should discuss how the application is modified in response to previous review comments..

   Upload as a PDF file. Click "**Attach File**" and select the file to be uploaded in the application.

   e.g., 2025ACRA_Resubmission_your last name

   After completing this form, click **"Mark as Complete"**.

10. **Personal Statement Form (required).**
    Enter answers to the following questions. Cutting and pasting from a Word document is allowed. Each response must not exceed 2,000 characters.

- Career plan and impact of award. Provide a brief description of the applicant's career plan and explain how receiving this award would affect the applicant's career.
- Percentage time of research activities. Provide the percentage of time the applicant will spend on total research activities during the award period.
- Salary support. List the applicant's sources of salary support during the award period.
- Collection and support of data. Briefly describe who will collect and analyze the data.
- Other funding sources. List other funding agencies/organization where this research proposal was or will be submitted. If none, please indicate N/A.

After completing this form, click **"Mark as Complete"**.

11. **Applicant's Biosketch (required).** Applicants should use the NIH biosketch template provided with an expiration date of 01/31/2026. The biosketch must not exceed more than five (5) pages. To complete the biosketch, please refer to these instructions. **If the document uploaded exceeds the page limit, Conquer Cancer will return the application.**

    Upload as a PDF file. Click "**Attach File**" and select the file to be uploaded in the application.

    Use this file naming convention: *2025ACRA_Biosketch_your last name*

    After completing this form, click **"Mark as Complete"**.

12. **Institutional Letter of Support from Department Chair or Dean (required).** A letter from the Department Chair or Dean from the applicant's sponsoring institution where the research project will be conducted must be provided. This letter must include a statement of institutional support that will enable the applicant to perform the proposed research and that the applicant will have at least 75% protected time for research during the award period. This letter must be signed and on official letterhead. **If the letter is not signed and not printed on official letterhead, Conquer Cancer will return the application.**

    Upload as a PDF file. Click "**Attach File**" and select the file to be uploaded in the application.

    Use this file naming convention: *2025ACRA_InstitutionalLOS_your last name*

    After completing this form, click **"Mark as Complete"**.

13. **Clinical Protocol (required).** For clinical studies or projects including specific aims as a part of a clinical trial, it is required to upload the clinical protocol.

    Upload as a PDF file. Click "**Attach File**" and select the file to be uploaded in the application.

    Use this file naming convention: *2025ACRA_ClinicalProtocol_your last name*

    After completing this form, click **"Mark as Complete"**.

14. **Letter from Drug Company (optional).** If the research project involves the use of a drug from a pharmaceutical company to perform the clinical trial/clinical study, it is strongly encouraged to submit a letter from the company to show support for the drug supply.

    Upload as a PDF file. Click "Attach File" and select the file to be uploaded in the application.

    Use this file naming convention: *2025ACRA_DrugLOS_your last name*

    After completing this form, click "**Mark as Complete**

15. **Publications (optional).** Up to two prior publications that highlight the applicant's experience and qualifications may be included. The applicant must be a co-author on these publications.

    To enter publications:
    - Select the total number of publications from the drop-down (1 or 2).
    - For each publication, enter the title, PubMed ID number, year, type, name, status, URL, and funding status.
    - Click "**Attach File**" and select the file(s) to be uploaded in the application.
    - Use this file naming convention: *e.g., 2025 ACRA_Publication 1_your last name*

    After completing this form, click **"Mark as Complete"**.

16. **Additional Supporting Documentation (optional).** This section may be used to upload any necessary additional information required to properly review the application (e.g., letters documenting the feasibility of the project, a letter of collaboration from another laboratory providing expertise for this project, a letter of support for a collaboration, etc.). Letters of support from collaborating biostatisticians and patient advocates are required. **All letters must be signed and on official letterhead.**

    Upload as a PDF file. Click "**Attach File**" and select the file to be uploaded in the application. Repeat this step to upload multiple files.

    Use this file naming convention: *2025ACRA_SupportingDoc_1_your last name; 2025ACRA_SupportingDoc_2_your last name; etc.*

    After completing this form, click **"Mark as Complete"**.

17. **Institution Approval (required).** The Authorized Official representing the sponsoring institution must approve the completed application (both the project proposal and the budget) before submission by completing the "Institution Approval" task. This individual is typically from the institution's Office of Sponsored Research.

    - To request a recommendation from the Institution Approver:
        - Click "**Request a Recommendation**".

  - Enter the First name, Last name, Email address, and write a message (optional) to the Institution Approver.
  - Click "**Send Request**". The Institution Approver will receive an email notification with the message.
  - If the Institution Approver accepts or decline the recommendation request, the applicant will receive an email notification.
- To resend or withdraw the request, click the ellipsis **(…)** near the Institution Approver's name and email and select the appropriate option from the drop-down list.
- **IMPORTANT:** The Institution Approver must complete their task and click "Submit" at the bottom of the page **prior** to the deadline. An email notification will be sent to the applicant confirming that the task has been completed.
- The applicant will not be able to submit the application until this task is submitted.
- Once the Institution Approver has submitted the task, return to this section and click **"Mark as Complete"**.

18. Review and Submit (required).

The applicant will not be able to navigate to this page until all required sections have been **"Marked as Complete"** and the Institution Approver task has been submitted.

On the left navigation, click **"Review"** to review or **"Submit"** to submit the application.

To download a copy of the application, click "**My Applications**". Click the ellipsis **(…)** on the specific application and click "**Download**".

On the next screen, select the desired options and click "**Download**".

A new tab will open. Once the download is ready, click "**Download**". The application will be downloaded as a zip file.

Appendix A. Terms & Conditions

The Applicant selected to receive an Advanced Clinical Research Award (ACRA) for Diversity and Inclusion in Breast Cancer Research, and their Sponsoring Institution, must execute a separate Terms and Conditions document with Conquer Cancer in order to receive an ACRA. This section of the RFP sets forth selected provisions of the Terms and Conditions that the Applicant and their Sponsoring Institution should review carefully before submitting an application for an ACRA. This RFP does not contain the complete Terms and Conditions document. Conquer Cancer reserves the rights to modify any of the provisions of the Terms and Conditions prior to execution by the Applicant and Sponsoring Institution.

Responsible Conduct of Research

(1) The Research Project will be conducted according to the highest scientific and ethical standards and in compliance with all applicable laws and regulations and with the policies of the Sponsoring Institution, including with respect to Sponsoring Institution's conflict of interest policies and procedures. To the extent policies of the Sponsoring Institution conflict with these Terms and Conditions, these Terms and Conditions will prevail.

(2) Upon request of Conquer Cancer, the Recipient will provide copies of documentation of Institutional Review Board approval for human research subjects to Conquer Cancer prior to commencing research on human subjects, if applicable.

(3) Upon request of Conquer Cancer, the Recipient will provide copies of documentation of Institutional Animal Care and Use Committee approval or international animal welfare board equivalent to Conquer Cancer prior to commencing research on animal subjects, if applicable.

Funds: Payment and Use

(4) The Award total is $450,000, paid in three annual installments of $150,000, on or about July 1, 2025, 2026, and 2027, subject to compliance by Recipient and Sponsoring Institution with these Terms and Conditions. The Award funds will be paid to the Sponsoring Institution.

(5) The Award will be used solely as detailed in the Research Project (including the grant proposal and budget).

(6) No more than 7 percent of total costs will be applied to overhead or indirect costs of the Sponsoring Institution in administering the Research Project. At least $137,500 per year of the Award funds will be applied to research support. No more than $2,500 per year will be used to cover the Recipient's travel expenses (including to the ASCO Annual Meeting). Direct costs include costs related to sub-grants and subcontracts. Salary limits will be equivalent to the NIH applicable limit.

(7) Conquer Cancer will not make payment of the next installment of Conquer Cancer Funds unless the Recipient expends at least 80 percent of their yearly budget by the end of the applicable reporting year, or the Recipient has submitted an explanation that is satisfactory to Conquer Cancer, in its sole discretion, as to why this requirement was not met.

(8) Award funds will not be used for expenditures incurred prior to the first day of the Award Period (except for expenses related to travel to the Conquer Cancer Grants and Awards Ceremony) or after the last day of the Award Period. No additional expenses may be paid from Award funds after Conquer Cancer has received the Recipient's final expenditure report or after any unexpended funds have been returned to Conquer Cancer, which must be provided in accordance with specific paragraphs in the full Terms and Conditions.

(9) At the end of the Award Period, any unexpended funds and any funds expended inconsistent with the Research Project will be returned to Conquer Cancer.

(10) If the Research Project included budgeted subcontracts to other institutions, Recipient will be responsible for obtaining budget summaries and progress information annually, in concordance with the reporting schedule set forth herein. All consortium and contractual agreements will be subject to and will comply with these Terms and Conditions. Recipient will ensure that the Research Project is conducted in compliance with these Terms and Conditions.

(11) With prior written approval from Conquer Cancer, Recipient may subcontract with a third party even if not budgeted in the original research proposal. A request to reallocate the budget will be submitted to Conquer Cancer through Conquer Cancer's application portal for approval and will include a description of the work to be performed by the third party, reason for contracting with the third party, and a complete budget for the third party including revisions to the original budget categories. All contractual agreements will be subject to and will comply with these Terms and Conditions.

(12) Award funds not expended in the year for which they were budgeted may be carried over to the same budget component in the next year of the Award Period without prior approval of Conquer Cancer. However, a detailed justification of why funds were not expended and how they will be expended in the following year will be included in the expenditure report.

Requests for Budget Changes or Extensions

(13) The Recipient may move funds of up to 5 percent of the total yearly budget ($7,500) between budget categories or into new budget categories without prior written approval of Conquer Cancer. Notwithstanding the foregoing, budget limits on indirect and travel costs will be strictly followed and cannot be adjusted.

(14) Budget changes of greater than 5 percent per year between budget categories will be approved in writing by Conquer Cancer before expenditure of funds. The Recipient will submit a re-budget request with a detailed justification of the proposed change through the application portal.

(15) Any request for a no-cost extension or budget change must be made through the application portal no earlier than 90 days prior to the expiration of the Award Period. Requests received after the last day of the Award Period will not be accepted and will automatically be disapproved. No cost-extensions of up to six months may be approved by Conquer Cancer in its sole discretion. Conquer Cancer may approve up to a maximum of three no-cost extensions.

(16) Requests for a six month no-cost extension require a no-cost-extension request submission through the application portal and a detailed explanation of why the request is being made. Requests will only be approved if they pertain to Research Project. Conquer Cancer will approve or disapprove the request at its discretion.

(17) If a no-cost extension is granted by Conquer Cancer, the Recipient will submit additional progress reports and financial expenditure reports every six months during the extension term.

Change of Personnel

(18) The Recipient is not permitted to transfer the Award to a co-investigator or any member of the research team.

Changes in Research Focus and Project Scope

(19) Changes in the specific aims of the Research Project will not be allowed without prior written consent from Conquer Cancer. Any request for changes in the specific aims of the Research Project must be made through the application portal prior to performing any changes to the Research Project. Conquer Cancer will approve or disapprove the request at its discretion.

(20) Major changes in research design require prior written approval from Conquer Cancer. A request must be submitted by the Recipient through the application portal prior to performing any aspects of any newly designed study. Examples of a major change include, but are not limited to, studying a different patient population than originally proposed or studying a different therapeutic than originally proposed.

(21) Minor changes in research methodology are not subject to prior approval by Conquer Cancer but must be explained and justified by the Recipient in the annual progress report.

Institution Transfer

(22) If the Recipient accepts an appointment at another institution during the Award Period, and desires to have the Research Project transferred to the new institution, the Recipient will submit a request through the application portal to transfer the Award to the new institution at least 60 days before the anticipated date of transfer. Subject to Conquer Cancer's written approval and in Conquer Cancer's sole discretion, the Award may be transferred provided arrangements satisfactory to Conquer Cancer are implemented to continue the Research Project in a manner in

which it was originally approved by Conquer Cancer. Any transfer must be approved in writing by Conquer Cancer before any such transfer takes place. Upon approval of a transfer of the Award to a new institution, the Sponsoring Institution will return any unexpended funds and any funds expended inconsistent with the Research Project to Conquer Cancer. The new institution will agree to comply with these Terms and Conditions. Conquer Cancer will make arrangements to provide remaining Award funds to the new institution.

(23) If the Recipient is unable or not permitted to transfer the grant to a new institution, the Recipient and the Sponsoring Institution will relinquish the Award and any unexpended funds and funds expended inconsistent with the Research Project will be returned to Conquer Cancer.

Program Reporting

(24) Throughout the Award Period, the Recipient will submit expenditure reports and progress reports regarding the Research Project through the application portal. It is the responsibility of the Recipient to submit the reports in a timely manner. Conquer Cancer may contact appropriate persons connected to the Research Project to ensure the progress reports and expenditure reports are received as required. Recipient and Sponsoring Institution will comply with the then-current procedures of Conquer Cancer regarding submission of progress and expenditure reports.

(25) Noncompliance with any of these Terms and Conditions, including failure to submit progress or expenditure reports, may result in the withholding of payment on this Award or other awards of Conquer Cancer in effect at the Sponsoring Institution, or on Conquer Cancer awards that may be awarded in the future, or such other action deemed appropriate by Conquer Cancer.

(26) Any unobligated balance must be returned in full to Conquer Cancer along with the final expenditure report. The check should be made payable to the “Conquer Cancer, the ASCO Foundation.”

Post-Award Reporting Obligation

(27) The Recipient will respond to Conquer Cancer's requests for information on their career progress following the Award Period and may be requested to provide their current Curriculum Vitae or update their information through the application portal using the “Career Progress” task. The information may be used for program evaluation and alumni communications. The Recipient understands that this obligation survives the Award Period and that they have an ongoing obligation to provide this information.

(28) Conquer Cancer reserves the right to include information relating to the Award in its periodic reports, annual reports, awardee directory, publicly accessible databases of privately funded grant awards, or in any other materials issued by or on behalf of Conquer Cancer or Conquer Cancer’s affiliates.

Provision of Information to Breast Cancer Research Foundation

(29) The Recipient acknowledges, agrees, and consents to Conquer Cancer providing their current and future contact information to Breast Cancer Research Foundation.

(30) The Recipient acknowledges, agrees, and consents to Conquer Cancer providing progress and expenditure reports and copies of press releases relating to the Award or the Research Project to Breast Cancer Research Foundation.

(31) The Recipient authorizes Breast Cancer Research Foundation to add the Award amount to the Recipient's ORCID profile.

Publications and Other Public Release of Results

(32) Conquer Cancer strongly encourages Recipient to submit the results of Research Project for publication or other public release. In the event the Recipient's results are published or otherwise publicly released either during or after the Award Period, the Recipient will provide Conquer Cancer with a copy of such publication or public release. All publications and public releases will include an acknowledgment of Conquer Cancer and Breast Cancer Research Foundation (see Public Announcements and Acknowledgment).

(33) Conquer Cancer supports the widest possible dissemination of funded research results. Recipient is highly encouraged to publish in scientific journals that will provide public access to the research findings no later than twelve months after the date of publication.

Public Announcements and Acknowledgments

(34) Conquer Cancer will announce the Award and other recipients of the Conquer Cancer Advanced Clinical Research Award. Conquer Cancer anticipates that the Sponsoring Institution may wish to make a public announcement of this Award. The Sponsoring Institution will submit to Conquer Cancer any proposed announcement, press release, or other public statement by the Sponsoring Institution relating to the Award, prior to release, and to coordinate the release of such public announcement, press release, or statement with Conquer Cancer. A copy of any press release, announcement, or public statement must be provided to Conquer Cancer.

(35) The Recipient and the Sponsoring Institution will acknowledge the support of Conquer Cancer and Breast Cancer Research Foundation in all publications and presentations of the research funded by the Award. The Recipient understands that all abstracts, publications, and presentations resulting from research supported by the Award will contain the acknowledgment, "This work was funded by a Conquer Cancer Advanced Clinical Research Award, supported by Breast Cancer Research Foundation. Any opinions, findings, and conclusions expressed in this

material are those of the author(s) and do not necessarily reflect those of the American Society of Clinical Oncology® or Conquer Cancer®, or Breast Cancer Research Foundation."

(36) The Recipient is encouraged to use an emblem for the Conquer Cancer Advanced Clinical Research Award and Breast Cancer Research Foundation's logo on posters, presentations, and similar items produced for scientific meetings and conferences. The emblem may be used with the acknowledgment language. The Recipient can request this emblem and Breast Cancer Research Foundation's logo by sending an email to grants@conquer.org

Intellectual Property Rights

(37) Conquer Cancer and the Breast Cancer Research Foundation will have no intellectual property rights or other rights in or to data collected or scientific discoveries made through the Research Project funded by the Award. Conquer Cancer encourages its recipients and their sponsoring institutions to report to Conquer Cancer any inventions, discoveries, or intellectual properties that result from the support of the research.

Appendix B. Helpful Tips for Using the Application Portal

Getting Started

To access the application portal, go to **awards.asco.org**

- *If you have an existing ASCO account,* use your ASCO credentials to log into the application portal. If you are having issues logging in, click the "Need Help?" link in the "Log-in" page.
- *If you do not have an ASCO account,* go to awards.asco.org and click "Log-in" in the top right corner of the screen. On the next screen, click "Create Account" and follow the prompts to complete your account setup and create a password. After your account is set up, you will be returned to the application portal.
- *To initiate an application,* once logged into the application portal, click "View Programs", select the program "Advanced Clinical Research Award", and click "**Apply**".
- *NOTE:* Make sure that your ASCO membership profile has the most up-to-date information before beginning an application

Completing the Eligibility Quiz

You will first be asked to complete an eligibility quiz. Once you have answered each question, click "**Mark as Complete**" at the bottom of the page. You will then receive an email to confirm your eligibility. If you are eligible, you will automatically have access to the letter of intent. The different application tasks will appear in the left navigation. If you have any questions regarding eligibility, contact grants@conquer.org.

Navigating the Application

- Click "Save and Continue Editing" at the bottom of the page as you go through the application.
- When finished with a particular task (e.g., Project Information), click "Mark as Complete" at the bottom of the page to validate task completion.
- If you need to edit a task after it has been Marked as Complete, click the ellipsis **(…)** on the top right corner of the task as shown below. Select "Edit" to reopen the form.
    - *IMPORTANT! Do NOT click "Reset" as this will delete previously entered data!*

Uploading a Document

- Click “Show accepted formats” to determine the file formats accepted. Documents should not be password protected.
- Documents must follow the file naming convention and requirements for page limits, margins, and fonts (see individual application sections for details). **If any document you uploaded does not meet the specific criteria, Conquer Cancer will return your application.**
- To upload a document, click “**Attach File**” and select the file to be uploaded.
- To edit a file name, click the ellipsis **(…)** next to the file name as shown below. Select “Edit” and enter the new file name based on the file naming convention.
- To remove or replace an uploaded document, click the ellipsis **(…)** next to the file name as shown below. Select “Remove” then click “Attach File”.



Requesting a Recommendation

- As part of your application process, you will need to "Request a Recommendation" from third parties such as an Institution Approver. Click on the task and fill in the details of the Recommender including the First Name, Last Name, Email, and a brief message (optional) to send the Recommender. Once the information is submitted, an automated email will be sent to the Recommender letting them know that they've been asked to provide a recommendation. When the recommendation is submitted, you will be instantly notified.
- If the Recommender didn't receive an email invite, confirm that you sent the invite to the correct email address and there are no spelling errors, ask the Recommender to check their junk/spam folder, or resend the Invitation.
- To resend or withdraw the request, click the ellipsis **(…)** near the Recommender's name and email and select the appropriate option from the drop-down list as shown below.



Receiving Notifications

Add awards@mail.asco.org and grants@conquer.org to your safe senders list to ensure you receive timely notifications associated with recommender task submissions, application submissions, etc. If you are not receiving notifications, check your junk/spam folders first, then contact grants@conquer.org for additional assistance.

Appendix C: Application Information Use and Sharing

Conquer Cancer may use and process the information submitted through this application form for several purposes, including but not limited to: 1) evaluating the application, 2) communicating with you regarding your application and other opportunities that may be of interest to you, 3) publishing information regarding Conquer Cancer's grants and awards program, including through third party databases, 4) informing Conquer Cancer's grant making strategies and policies, and 5) for other legitimate purposes in keeping with Conquer Cancer's Privacy Policy and charitable mission. Information submitted through this application form will be kept on secure servers accessible to Conquer Cancer personnel and third parties authorized by Conquer Cancer to perform functions on Conquer Cancer's behalf.

In addition, by submitting an application form to Conquer Cancer, the applicant grants Conquer Cancer the right to use all application information submitted, outside of the research proposal, for any purpose.

The details of research proposals submitted are considered confidential property of the applicant. Conquer Cancer is permitted to share research proposals with Conquer Cancer staff and reviewers, third party contractors, and potential supporters, and Conquer Cancer will require all to maintain the confidentiality of such proposals.

If an applicant is selected for an award, the applicant grants Conquer Cancer permission to deposit grantee information collected in any documents or communications related to the application (including but not limited to investigator name, degree(s), clinical specialty, Open Researcher and Contributor ID (ORCID), institution and institutional information, project title, abstract, grant start date and duration, and grant amount) into the Health Research Alliance (HRA) online database (HRA Analyzer) of privately funded grants, the Dimensions database, or any other similar database.

If an applicant is deemed fundable but Conquer Cancer does not have funding available, the applicant grants Conquer Cancer permission to share the full proposal to potential supporters.

Appendix D: Compliance with Applicable Legal Requirements (Applies to Non-U.S. Institutions and Entities)

The award of the ACRA is subject to applicable financial and legal requirements, including but not limited to United States laws addressing foreign corrupt practices and economic and trade sanctions and embargoes (including but not limited to those administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury). Notwithstanding any other provision in this this Request for Proposals, any grant award is contingent on Conquer Cancer's ability to transfer grant funds to the sponsoring institution and/or individual(s) and support the research project to be conducted by the applicant in compliance with all applicable legal requirements. **Conquer Cancer will not accept applications from, and/or make grant awards to, certain foreign sponsoring institutions or individuals if Conquer Cancer is prohibited from doing so under U.S. sanctions laws, or if Conquer Cancer would be required to obtain a license from the Office of Foreign Assets Control or the Department of Commerce to make such grants**. If it is impossible or inadvisable for Conquer Cancer, in its sole and absolute discretion, to transfer grant funds to the sponsoring institution and/or individual(s) pursuant to applicable legal requirements, the grant will not be awarded to the sponsoring institution and/or individual. If, after payment of the first installment of a grant award, it becomes impossible or inadvisable for Conquer Cancer, in its sole and absolute discretion, to fulfill its obligations in a grant award, including but not limited to the transfer of grant funds to the sponsoring institution and/or individual(s) pursuant to applicable legal requirements, then Conquer Cancer shall have no obligation to pay additional installments of the grant award. It is the responsibility of the sponsoring institution and the applicant to provide Conquer Cancer with the information or lawful means that permit Conquer Cancer to transfer the grant funds in compliance with all legal requirements.

Among the resources available to evaluate compliance with requirements administered by the Office of Foreign Assets Control are:

- http://www.treasury.gov/resource-center/sanctions/Pages/default.aspx
- http://www.treasury.gov/resource-center/sanctions/Programs/Pages/Programs.aspx
- http://www.treasury.gov/resource-center/sanctions/SDN-List/Pages/default.aspx

For more information, see Terms and Conditions located in Appendix A.